MedTrace Logo

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

NCT04566666 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2026-01-20

Study results available
· View outcomes & findings →

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

Placebo

Placebo of SCD-044 product

DRUG

SCD-044_Low Dose (Dose 1)

SCD-044 tablets in Low Dose (Dose 1)

DRUG

SCD-044_Intermediate Dose (Dose 2)

SCD-044 tablets in Intermediate Dose (Dose 2)

DRUG

SCD-044_High Dose (Dose 3)

SCD-044 in High Dose (Dose 3)

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-25
Primary Completion
2024-11-20
Completion
2025-08-27
FDA Drug
Yes

Countries

  • United States
  • El Salvador
  • Estonia
  • Georgia
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04566666 on ClinicalTrials.gov